产科产前携带者筛查时进行BRCA1检测用于癌症预防的成本效益
该研究采用决策分析和马尔可夫模型,模拟美国每年接受扩展携带者筛查的1,429,074名孕妇,评估在产科产前携带者筛查时加入BRCA1检测的成本效益。结果显示BRCA1检测可额外识别3716名BRCA1阳性患者,预防1394例乳腺癌和卵巢癌,减少1084例死亡,增量成本效益比为每质量调整生命年86,001美元,结论为具有成本效益。
要点
- 在产科产前携带者筛查时加入BRCA1检测,可额外识别3716名BRCA1阳性患者。
- 该策略可预防1394例乳腺癌和卵巢癌,并减少1084例死亡。
- 增量成本效益比为每质量调整生命年86,001美元,具有成本效益。
核心结论
- 在产科产前携带者筛查中加入BRCA1检测是一种具有成本效益的管理策略,可在癌症筛查和预防策略有效的时机识别高危女性。
- 尽管会增加遗传咨询负担,但产前保健为实施人群-based基因检测提供了独特机会。
研究设计与样本
- 研究采用决策分析和马尔可夫模型,初始决策点为在扩展携带者筛查时进行BRCA1检测。
- 模型概率、成本和效用值来自已发表文献,对BRCA1阳性患者模拟乳腺癌筛查和降低风险手术干预。
- 模型周期长度为1年,时间跨度47年,模拟患者终生。
- 研究设定为美国产科门诊,参与者为每年接受扩展携带者筛查的理论队列1,429,074名孕妇。
主要发现
- 在该队列中,BRCA1检测额外识别了3716名BRCA1阳性患者。
- BRCA1检测预防了1394例乳腺癌和卵巢癌,并减少了1084例死亡。
- 与不进行BRCA1检测相比,BRCA1检测的增量成本效益比为每质量调整生命年86,001美元。
- 在单因素敏感性分析中,BRCA1人群患病率在0.00%至20.00%范围内变动时,BRCA1检测持续具有成本效益,直至患病率降至0.16%。
- 多项额外敏感性分析未对成本效益产生实质性影响。
关键数值与推荐
- BRCA1检测的增量成本效益比为每质量调整生命年86,001美元。
- 单因素敏感性分析中,BRCA1患病率从0.00%至20.00%变动,检测在患病率降至0.16%前持续具有成本效益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved technologies paired with an increase in access to genetic testing have led to the availability of expanded carrier screening evaluating hundreds of disorders. Currently, most autosomal dominant mutations, such as BRCA1, are not included in expanded carrier assays. Screening pregnant or preconception reproductive-aged women for BRCA1 may present a unique opportunity to perform population-based screening for patients at a time when precancer screening, chemoprevention, and/or risk-reducing surgery may be beneficial. OBJECTIVE: This study aimed to inform clinical decision-making as to whether the universal incorporation of BRCA1 testing at the time of obstetrical prenatal carrier screening is cost-effective. STUDY DESIGN: A decision analysis and Markov model was created. The initial decision point in the model was BRCA1 testing at the time of expanded carrier screening. Model probabilities, cost, and utility values were derived from published literature. For BRCA1-positive patients, the model simulated breast cancer screening and risk-reducing surgical interventions. A cycle length of 1 year and a time horizon of 47 years were used to simulate the lifespan of patients. The setting was obstetrical clinics in the United States, and the participants were a theoretical cohort of 1,429,074 pregnant patients who annually underwent expanded carrier screening. RESULTS: Among our cohort, BRCA1 testing resulted in the identification of an additional 3716 BRCA1-positive patients, the prevention of 1394 breast and ovarian cancer cases, and 1084 fewer deaths. BRCA1 testing was a cost-effective strategy compared with no BRCA1 testing with an incremental cost-effectiveness ratio of $86,001 per quality-adjusted life years. In a 1-way sensitivity analysis, we varied the prevalence of BRCA1 in the population from 0.00% to 20.00% and found that BRCA1 testing continued to be the cost-effective strategy until the prevalence rate was reduced to 0.16%. Multiple additional sensitivity analyses did not substantially affect the cost-effectiveness. CONCLUSION: The addition of BRCA1 testing to obstetrical prenatal carrier screening is a cost-effective management strategy to identify at-risk women at a time when cancer screening and preventive strategies can be effective. Despite the burden of additional genetic counseling, prenatal care represents a unique opportunity to implement population-based genetic testing.
引用
- Dioun SM, Perez LR, Prabhu M, et al. Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention. Am J Obstet Gynecol. 2024. PMID: 38621481. doi:10.1016/j.ajog.2024.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。